Taurine counteracts oxidative stress and nerve growth factor deficit in early experimental diabetic neuropathy

被引:149
|
作者
Obrosova, IG
Fathallah, L
Stevens, MJ
机构
[1] Univ Michigan, Med Ctr, Dept Internal Med, Div Endocrinol & Metab, Ann Arbor, MI 48109 USA
[2] Vet Affairs Med Ctr, Ann Arbor, MI 48105 USA
关键词
ascorbate; glutathione; 4-hydroxy-alkenals; malondialdehyde; nerve growth factor; oxidative stress; rat; sciatic nerve; streptozotocin-induced diabetes; taurine;
D O I
10.1006/exnr.2001.7789
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Oxidative stress has a key role in the pathogenesis of diabetic complications. We have previously reported that taurine (T), which is known to counteract oxidative stress in tissues (lens, kidney, retina) of diabetic rats, attenuates nerve blood flow and conduction deficits in early experimental diabetic neuropathy (EDN). The purpose of this study was to evaluate whether dietary T supplementation counteracts oxidative stress and the nerve growth factor (NGF) deficit in the diabetic peripheral nerve. The experiments were performed in control rats and streptozotocin-diabetic rats fed standard or 1% T-supplemented diets for 6 weeks. All measurements were performed in the sciatic nerve. Malondialdehyde (MDA) plus 4-hydroxyalkenals (4-HA) were quantified with N-methyl-2-phenylindole. GSH, GSSG, dehydroascorbate (DHAA), and ascorbate (AA) were assayed spectrofluorometrically, T by reverse-phase HPLC, and NGF by ELISA. MDA plus 4-HA concentration (mean +/- SEM) was increased in diabetic rats (0.127 +/-0.006 vs 0.053 +/-0.003 mu mol/g in controls, P<0.01), and this increase was partially prevented by T (0.096<plus/minus>0.004, P<0.01 vs untreated diabetic group). GSH levels were similarly decreased in diabetic rats treated with or without taurine vs controls. GSSG levels were similar in control and diabetic rats but were lower in diabetic rats treated with T (P<0.05 vs controls). AA levels were decreased in diabetic rats (0.133+0.015 vs 0.219 +/-0.023 mu mol/g in controls, P<0.05), and this deficit was prevented by T. DHAA/AA ratio was increased in diabetic rats vs controls (P<0.05), and this increase was prevented by T. T levels were decreased in diabetic rats (2.7 +/-0.16 vs 3.8 +/-0.1 mu mol/g in controls, P<0.05) and were repleted by T supplementation (4.2<plus/minus>0.3). NGF levels were decreased in diabetic rats (2.35 +/-0.20 vs 3.57 +/-0.20 ng/g in controls, P<0.01), and this decrease was attenuated by T treatment (3.16<plus/minus>0.28, P<0.05 vs diabetic group). In conclusion, T counteracts oxidative stress and the NGF deficit in early EDN. Antioxidant effects of T in peripheral nerve are, at least in part, mediated through the ascorbate system of antioxidative defense. The findings are consistent with the important role for oxidative stress in impaired neurotrophic support in EDN. (C) 2001 Academic Press.
引用
收藏
页码:211 / 219
页数:9
相关论文
共 50 条
  • [31] Nerve growth factor (NGF) for the treatment of diabetic neuropathy. Is there hope?
    Quasthoff, S
    Hartung, HP
    NERVENARZT, 2001, 72 (06): : 456 - 459
  • [32] NERVE GROWTH-FACTOR PREVENTS EXPERIMENTAL CISPLATIN NEUROPATHY
    APFEL, SC
    AREZZO, JC
    LIPSON, L
    KESSLER, JA
    ANNALS OF NEUROLOGY, 1992, 31 (01) : 76 - 80
  • [33] Oxidative stress in the pathogenesis of diabetic neuropathy
    Vincent, AM
    Russell, JW
    Low, P
    Feldman, EL
    ENDOCRINE REVIEWS, 2004, 25 (04) : 612 - 628
  • [34] Oxidative stress and antioxidants in diabetic neuropathy
    Guler, E. M.
    Borucu, D.
    Yalcin, A. D.
    Yalcin, A. S.
    FEBS JOURNAL, 2014, 281 : 378 - 378
  • [35] DIABETIC NEUROPATHY, NERVE GROWTH-FACTOR AND OTHER NEUROTROPHIC FACTORS
    BREWSTER, WJ
    FERNYHOUGH, P
    DIEMEL, LT
    MOHIUDDIN, L
    TOMLINSON, DR
    TRENDS IN NEUROSCIENCES, 1994, 17 (08) : 321 - 325
  • [36] AN INVESTIGATION OF ANTIBODIES TO NERVE GROWTH-FACTOR IN DIABETIC AUTONOMIC NEUROPATHY
    ZANONE, MM
    BANGA, JP
    PEAKMAN, M
    EDMONDS, M
    WATKINS, PJ
    DIABETIC MEDICINE, 1994, 11 (04) : 378 - 383
  • [37] LOW SERUM LEVELS OF NERVE GROWTH-FACTOR IN DIABETIC NEUROPATHY
    FARADJI, V
    SOTELO, J
    ACTA NEUROLOGICA SCANDINAVICA, 1990, 81 (05): : 402 - 406
  • [38] Nerve growth factor and expression of its receptors in patients with diabetic neuropathy
    Kim, H. C.
    Cho, Y. J.
    Ahn, C. W.
    Park, K. S.
    Kim, J. C.
    Nam, J. S.
    Im, Y. S.
    Lee, J. E.
    Lee, S. C.
    Lee, H. K.
    DIABETIC MEDICINE, 2009, 26 (12) : 1228 - 1234
  • [39] THE ROLE OF NERVE GROWTH-FACTOR IN THE PATHOGENESIS AND THERAPY OF DIABETIC NEUROPATHY
    SCHMIDT, RE
    DIABETIC MEDICINE, 1993, 10 (05) : S10 - S13
  • [40] Nerve growth factor and oxidative stress in the nervous system
    Pan, ZH
    Sampath, D
    Jackson, G
    Werrbach-Perez, K
    Perez-Polo, R
    BRAIN PLASTICITY: DEVELOPMENT AND AGING, 1997, 429 : 173 - 193